Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $2.4M fell 3.2% year over year, behind the +1.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +47.6% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.2% toward the trailing-twelve-month pace of +1.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.85M USD
- Year-over-year change
- +2.3%
- 4-year CAGR
- +80.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.85M | +2.3% |
| FY2024 | 2024-12-31 | 9.64M | +56.8% |
| FY2023 | 2023-12-31 | 6.15M | +100.8% |
| FY2022 | 2022-12-31 | 3.06M | +232.0% |
| FY2021 | 2021-12-31 | 922K | — |
Stock-Based Compensation vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 stock-based compensation of $9.77M is the 6th largest of the 10 companies compared; the peer median is $9.79M.
- Its year-over-year change of +1.5% is the 3rd highest of 10, against a peer median of -43.4%.
- Over three fiscal years its annual growth of +47.6% compares with a peer median of -22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.47M | -43.3% | -31.8% | 340.0% | |
| LTM Mar 2026 | $21.22M | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $9.79M | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $9.77M | +1.5% | +47.6% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6.28M | +111.2% | +109.9% | — |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $3.88M | -47.0% | -22.0% | 7.1% | |
| LTM Mar 2026 | $3.06M | -44.1% | -45.0% | — | |
| Peer median (excluding ABOS) | $9.79M | -43.4% | -22.0% | 85.6% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | (751K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 922K | 3.06M | 6.15M | 9.64M | 9.85M |
| Change in Working Capital | 298K | 3.99M | 3.87M | 11.65M | (5.12M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 557K | 552K | (261K) | 4.27M | (5.09M) |
| Other Working Capital | (259K) | 3.43M | 4.13M | 7.38M | (25K) |
| Other Non-Cash Items | 81.42M | 487K | (888K) | (5.35M) | 1.82M |
| Operating Cash Flow | (17.96M) | (35.15M) | (43.06M) | (86.22M) | (115.54M) |
| Capital Expenditures | (40K) | (161K) | (21K) | (16K) | (88K) |
| Acquisitions (Net) | 0 | (39.35K) | 3K | 0 | 0 |
| Purchases of Investments | (104.08M) | (41.51M) | (250.63M) | (170.73M) | (38.06M) |
| Sales of Investments | 0 | 80.86M | 78.98M | 218.77M | 172.08M |
| Other Investing Activities | 0 | 39.35K | 0 | 0 | 0 |
| Investing Cash Flow | (104.12M) | 39.19M | (171.67M) | 48.03M | 133.93M |
| Debt Repayment | 0 | 0 | 30M | (739K) | 0 |
| Common Stock Issued | 168.56M | 3.79M | 121.9M | 7.94M | 39K |
| Common Stock Repurchased | 0 | 0 | 0 | (41K) | (73K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.88M | 115K | (151K) | (230K) | 0 |
| Financing Cash Flow | 200.47M | 3.91M | 151.75M | 6.93M | (34K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 78.39M | 7.94M | (62.98M) | (31.26M) | 18.36M |
| Free Cash Flow | (18M) | (35.31M) | (43.09M) | (86.23M) | (115.63M) |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.